{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:47:18Z","timestamp":1768884438071,"version":"3.49.0"},"reference-count":20,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The efficacy and safety of zanubrutinib, a highly selective next-generation Bruton's tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia and lymphoplasmocytoides immunocytoma seems favorable. Adverse events comprise neutropenia, thrombocytopenia, infection, anemia, and atrial fibrillation. This report describes a 75-year-old man suffering from polydipsia, polyuria, and blurred vision for 10 days. He was diagnosed with lymphoplasmocytoides immunocytoma in 2003. After various therapies, he was started on zanubrutinib in October 2022. A diagnosis of diabetes mellitus had never been established before. On arrival in the emergency department, his plasma glucose was 37.2\u2005mmol\/L (671\u2005mg\/dL) and glycated hemoglobin (HbA1c) was 14.2%. Circulating antibodies showed positivity for glutamic acid decarboxylase (GAD-65), and his C-peptide level was 1.3\u2005nmol\/L (normal range, 0.37-1.47\u2005nmol\/L), equivalent to 3.9\u2005ng\/mL (normal range 1.1-5.0\u2005ng\/mL). From the patient's medical history, it became obvious that the metabolic situation had been problematic for many years, and that diabetes could have been taken into account at least in the summer of 2020 when HbA1c was 6.7%. In patients on tyrosine kinase inhibitors, careful assessment of glycemic control (monitoring HbA1c and blood glucose levels periodically even for nondiabetic patients) is recommended to prevent a major diabetic emergency.<\/jats:p>","DOI":"10.1210\/jcemcr\/luad172","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:30:10Z","timestamp":1704472210000},"source":"Crossref","is-referenced-by-count":2,"title":["Severe Hyperglycemia Due to Protein Kinase Inhibitor Therapy in a Patient With Poorly Controlled Diabetes Mellitus"],"prefix":"10.1210","volume":"2","author":[{"given":"Isabel","family":"Sontag","sequence":"first","affiliation":[{"name":"Zentrale Notfallambulanz, Klinikum Leverkusen, Academic Hospital of the University of Cologne , Am Gesundheitspark 11, D\u201451375 Leverkusen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Med. Klinik 2, Klinikum Leverkusen, Academic Hospital of the University of Cologne , Am Gesundheitspark 11, D\u201451375 Leverkusen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6377-0999","authenticated-orcid":false,"given":"Henning Ernst","family":"Adamek","sequence":"additional","affiliation":[{"name":"Med. Klinik 2, Klinikum Leverkusen, Academic Hospital of the University of Cologne , Am Gesundheitspark 11, D\u201451375 Leverkusen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"8","key":"2024010516300668200_luad172-B1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1021\/cr000230w","article-title":"Kinetic and catalytic mechanisms of protein kinases","volume":"101","author":"Adams","year":"2001","journal-title":"Chem Rev"},{"issue":"1","key":"2024010516300668200_luad172-B2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","article-title":"Protein tyrosine kinase structure and function","volume":"69","author":"Hubbard","year":"2000","journal-title":"Annu Rev Biochem"},{"issue":"12","key":"2024010516300668200_luad172-B3","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/pharmaceutics13122201","article-title":"The TKI era in chronic leukemias","volume":"13","author":"De Novellis","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"2024010516300668200_luad172-B4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/13543784.2013.802768","article-title":"Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes","volume":"22","author":"Prada","year":"2013","journal-title":"Expert Opin Invest Drugs"},{"key":"2024010516300668200_luad172-B5","doi-asserted-by":"crossref","first-page":"694853","DOI":"10.3389\/fimmu.2021.694853","article-title":"Structure-function relationships of covalent and non-covalent BTK inhibitors","volume":"12","author":"Zain","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"2024010516300668200_luad172-B6","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1097\/HS9.0000000000000808","article-title":"First-line treatment with bendamustine and rituximab for old and frail patients with aggresive lymphoma: results of the B-R-ENDA trial","volume":"6","author":"Braulke","year":"2022","journal-title":"Hemasphere"},{"key":"2024010516300668200_luad172-B7","first-page":"1296","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Am Soc Hematol"},{"issue":"1","key":"2024010516300668200_luad172-B8","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibition in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"22","key":"2024010516300668200_luad172-B9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2024010516300668200_luad172-B10","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024010516300668200_luad172-B11","doi-asserted-by":"crossref","first-page":"R233","DOI":"10.1677\/ERC-10-0082","article-title":"Endocrine side effects of broad acting kinase inhibitors","volume":"17","author":"Lodish","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2024010516300668200_luad172-B12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Sunder","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"3","key":"2024010516300668200_luad172-B13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann d\u2019Endocrinol"},{"key":"2024010516300668200_luad172-B14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/01.HS9.0000847348.63031.af","article-title":"The efficiacy and safety of zanubrutinib and dexamethasone in symptomatic Waldenstrom macroglobulinemia","volume":"6","author":"Liu","year":"2022","journal-title":"HemaSphere"},{"key":"2024010516300668200_luad172-B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05486-x","article-title":"Efficacy and safety of new-genreation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and meta-analysis","author":"Yin","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"2024010516300668200_luad172-B16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"18","key":"2024010516300668200_luad172-B17","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2024010516300668200_luad172-B18","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2018-99-117464","article-title":"Glycemic control in patients treated with tyrosine kinase inhibitors for chronic myeloid leukemia: a systematic review","volume":"132","author":"Spatafora","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2024010516300668200_luad172-B19","first-page":"e220212","article-title":"Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin","volume":"256","author":"Duggan","year":"2023","journal-title":"J Endocrinol"},{"issue":"1","key":"2024010516300668200_luad172-B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/jcpt.12602","article-title":"Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantobodies with ibrutinib therapy of chronic lymphocytic leukaemia","volume":"43","author":"Skrabs","year":"2018","journal-title":"J Clin Pharm Ther"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/1\/luad172\/55115066\/luad172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/1\/luad172\/55115066\/luad172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:30:19Z","timestamp":1704472219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luad172\/7511714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,15]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luad172","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,15]]},"article-number":"luad172"}}